MedPacto, Inc. (235980.KQ)
KRW 4585.0
(-1.4%)
KRW 4585.0
(-1.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -32.6 Billion KRW | 23.91% |
| 2022 | -23.74 Billion KRW | -27.56% |
| 2021 | -7.18 Billion KRW | -5.21% |
| 2020 | -25.63 Billion KRW | -112.55% |
| 2019 | -12.33 Billion KRW | -24.38% |
| 2018 | -36.69 Billion KRW | -225.49% |
| 2017 | -2.91 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.72 Billion KRW | 52.52% |
| 2024 Q1 | -9.28 Billion KRW | -21.13% |
| 2023 Q4 | -7.2 Billion KRW | -25.24% |
| 2023 FY | - KRW | 23.91% |
| 2023 Q3 | -5.75 Billion KRW | 20.37% |
| 2023 Q2 | -7.22 Billion KRW | -7.44% |
| 2023 Q1 | -6.72 Billion KRW | 50.09% |
| 2022 Q2 | -6.7 Billion KRW | 30.42% |
| 2022 FY | - KRW | -27.56% |
| 2022 Q3 | -5.55 Billion KRW | 17.15% |
| 2022 Q4 | -13.47 Billion KRW | -142.58% |
| 2022 Q1 | -9.63 Billion KRW | -55.55% |
| 2021 Q1 | -5.22 Billion KRW | -68590.59% |
| 2021 Q3 | -8.61 Billion KRW | -11.91% |
| 2021 Q2 | -7.7 Billion KRW | -47.5% |
| 2021 Q4 | -6.19 Billion KRW | 28.09% |
| 2021 FY | - KRW | -5.21% |
| 2020 Q3 | -9.36 Million KRW | 0.0% |
| 2020 FY | - KRW | -112.55% |
| 2020 Q4 | -7.6 Million KRW | 18.81% |
| 2019 FY | - KRW | -24.38% |
| 2018 FY | - KRW | -225.49% |
| 2017 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 81.072% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | -423.021% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 399.931% |
| Bioneer Corporation | 10.04 Billion KRW | 424.683% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -7347.866% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | -68.158% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 23.807% |
| Helixmith Co., Ltd | -53 Billion KRW | 38.479% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 146.525% |
| Medy-Tox Inc. | 32.69 Billion KRW | 199.726% |
| Peptron, Inc. | -12.65 Billion KRW | -157.765% |
| Amicogen, Inc. | 13.95 Billion KRW | 333.7% |
| Genexine, Inc. | -40.87 Billion KRW | 20.23% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 496.236% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 54.32% |
| ALTEOGEN Inc. | 440.04 Million KRW | 7510.337% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 131.278% |
| SillaJen, Inc. | -17.35 Billion KRW | -87.919% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 396.233% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | -192.846% |
| Genomictree Inc. | -6.33 Billion KRW | -414.994% |
| D&D Pharmatech | -9.05 Billion KRW | -260.001% |
| EASY BIO,Inc. | 24.32 Billion KRW | 234.064% |
| GI Innovation, Inc. | -51.33 Billion KRW | 36.473% |